Bone turnover and hip bone mineral density in patients with sarcoidosis

Sarcoidosis Vasculitis and Diffuse Lung Diseases

Volumn 24, Issue 1, 2007, Pages 51-58

  Heijckmann, A Caroline ^a,b   Huijberts, Maya S P ^a   De Vries, Jolanda ^a,c   Menheere, Paul P C A ^a   Van Der Veer, Eveline ^d   Nieuwenhuijzen Kruseman, Arie C ^a   Wolffenbuttel, Bruce H R ^d   Geusens, Piet ^a,e   Drent, Marjolein ^a  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BERNHOVEN HOSPITAL   (Netherlands)

^c TILBURG UNIVERSITY   (Netherlands)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e HASSELT UNIVERSITY   (Belgium)

Author keywords

Bone mineral density; Bone turnover; Fractures; Metabolic bone disease; Osteoporosis; Sarcoidosis

Indexed keywords

CYTOKINE; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE TURNOVER; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GROUPS BY AGE; HIP; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; OSSIFICATION; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; SARCOIDOSIS; SCORING SYSTEM; SEX RATIO; SPINE; STATISTICAL SIGNIFICANCE; VERTEBRA MALFORMATION;

ADULT; AGED; BONE DENSITY; BONE REMODELING; BONE RESORPTION; FEMALE; FRACTURES, BONE; GLUCOCORTICOIDS; HIP; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; OSTEOPOROSIS; PEPTIDE FRAGMENTS; PROCOLLAGEN; RECEPTORS, INTERLEUKIN-2; SARCOIDOSIS;

EID: 36549024946     PISSN: 11240490     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Hunninghake GW, Costabel U, Ando M, et al: ATS/ERS/WASOG statement on sarcoidosis. American Thoracic Society/European Respiratory Society/World Association of Sarcoidosis and other Granulomatous Disorders. Sarcoidosis Vasc Diffuse Lung Dis 1999; 16: 149-73.
2. Baughman RP, Lower EE, du Bois RM: Sarcoidosis. Lancet 2003; 361: 1111-8.
3. Drent M, Wirnsberger RM, De Vries J, et al: Association of fatigue with an acute phase response in sarcoidosis. Eur Respir J 1999; 13: 718-22.
4. Hoitsma E, Marziniak M, Faber CG, et al: Small fibre neuropathy in sarcoidosis. Lancet 2002; 359: 2085-6.
5. Rizzato G: Clinical impact of bone and calcium metabolism changes in sarcoidosis. Thorax 1998; 53: 425-9.
6. Fallon MD, Perry HM, III, Teitelbaum SL: Skeletal sarcoidosis with osteopenia. Metab Bone Dis Relat Res 1981; 3: 171-4.
7. Tervonen S, Karjalainen P, Valta R: Bone mineral in sarcoidosis. Acta Med Scand 1974; 196: 497-503.
8. Rottoli P, Gonnelli S, Silitro S, et al: Alterations in calcium metabolism and bone mineral density in relation to the activity of sarcoidosis. Sarcoidosis 1993; 10: 161-2.
9. Conron M, Young C, Beynon HL: Calcium metabolism in sarcoidosis and its clinical implications. Rheumatology (Oxford) 2000; 39: 707-13.
10. Girgis RE, Basha MA, Maliarik M, et al: Cytokines in the bronchoalveolar lavage fluid of patients with active pulmonary sarcoidosis. Am J Respir Crit Care Med 1995; 152: 71-5.
11. Sahashi K, Ina Y, Takada K, et al: Significance of interleukin 6 in patients with sarcoidosis. Chest 1994; 106: 156-60.
12. Manolagas SC: The role of IL-6 type cytokines and their receptors in bone. Ann N Y Acad Sci 1998; 840: 194-204.
13. Scheidt-Nave C, Bismar H, Leidig-Bruckner G, et al: Serum interleukin 6 is a major predictor of bone loss in women specific to the first decade past menopause. J Clin Endocrinol Metab 2001; 86: 2032-42.
14. Montemurro L, Fraioli P, Rizzato G: Bone loss in untreated longstanding sarcoidosis. Sarcoidosis 1991; 8: 29-34.
15. Sipahi S, Tuzun S, Ozaras R, et al: Bone mineral density in women with sarcoidosis. J Bone Miner Metab 2004; 22: 48-52.
16. Adler RA, Funkhouser HL, Petkov VI, et al: Glucocorticoid-induced osteoporosis in patients with sarcoidosis. Am J Med Sci 2003; 325: 1-6.
17. Drent M, Jacobs JA, Cobben NA, et al: Computer program supporting the diagnostic accuracy of cellular BALF analysis: a new release. Respir Med 2001; 95: 781-6.
18. Quanjer PH, Tammeling GJ, Cotes JE, et al: Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: 5-40.
19. DeRemee RA: The roentgenographic staging of sarcoidosis. Historic and contemporary perspectives. Chest 1983; 83: 128-33.
20. Heijckmann AC, Huijberts MS, Geusens P, et al: Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma. Eur J Endocrinol 2005; 153: 23-9.
21. Duboeuf F, Bauer DC, Chapurlat RD, et al: Assessment of vertebral fracture using densitometric morphometry. J Clin Densitom 2005; 8: 362-8.
22. Genant HK, Wu CY, van KC, et al: Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993; 8: 1137-48.
23. Elders PJ, Netelenbos JC, Lips P, et al: Perimenopausal bone mass and risk factors. Bone Miner 1989; 7: 289-99.
24. Gravallese EM, Goldring SR: Cellular mechanisms and the role of cytokines in bone erosions in rheumatoid arthritis. Arthritis Rheum 2000; 43: 2143-51.
25. Pennisi P, Trombetti A, Rizzoli R: Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res 2006; 443: 39-47.
26. Canalis E, Bilezikian JP, Angeli A, et al: Perspectives on glucocorticoid-induced osteoporosis. Bone 2004; 34: 593-98.
27. Hofbauer LC, Schoppet M: Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 2004; 292: 490-5.
28. Hofbauer LC, Heufelder AE: The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis. Arthritis Rheum 2001; 44: 253-9.
29. Drent M, van den Berg R, Haenen GR, et al: NF-kappaB activation in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18: 50-6.
30. Culver DA, Barna BP, Raychaudhuri B, et al: Peroxisome proliferator-activated receptor gamma activity is deficient in alveolar macrophages in pulmonary sarcoidosis. Am J Respir Cell Mol Biol 2004; 30: 1-5.
31. Franchimont N, Wertz S, Malaise M: Interleukin-6: An osteotropic factor influencing bone formation? Bone 2005; 37: 601-6.
32. Muller-Quernheim J: Sarcoidosis: immunopathogenetic concepts and their clinical application. Eur Respir J 1998; 12: 716-38.
33. Rothkrantz-Kos S, van Dieijen-Visser MP, Mulder PG, et al: Potential usefulness of inflammatory markers to monitor respiratory functional impairment in sarcoidosis. Clin Chem 2003; 49: 1510-7.
34. Ganesan K, Teklehaimanot S, Tran TH, et al: Relationship of C-reactive protein and bone mineral density in community-dwelling elderly females. J Natl Med Assoc 2005; 97: 329-33.
35. Provvedini DM, Tsoukas CD, Deftos LJ, et al: 1,25-dihydroxy vitamin D3 receptors in human leukocytes. Science 1983; 221: 1181-3.
36. Clowes JA, Riggs BL, Khosla S: The role of the immune system in the pathophysiology of osteoporosis. Immunol Rev 2005; 208: 207-27.
37. Seeman E, Delmas PD: Bone quality - the material and structural basis of bone strength and fragility. N Engl J Med 2006; 354: 2250-61.
38. Chavassieux P, Seeman E, Delmas PD: Insights into material and structural basis of bone fragililty from diseases associated with fractures. How determinants of the biomechanical properties of bone are compromised by disease. Endocr Rev 2006.
39. O'Neill TW, Felsenberg D, Varlow J, et al: The prevalence of vertebral deformity in European men and women: the European Vertebral Osteoporosis Study. J Bone Miner Res 1996; 11: 1010-8.
40. McCloskey EV, Spector TD, Eyres KS, et al: The assessment of vertebral deformity: a method for use in population studies and clinical trials. Osteoporos Int 1993; 3: 138-47.
41. Eastell R, Cedel SL, Wahner HW, et al: Classification of vertebral fractures. J Bone Miner Res 1991; 6: 207-15.
42. Black DM, Palermo L, Nevitt MC, et al: Comparison of methods for defining prevalent vertebral deformities: the Study of Osteoporotic Fractures. J Bone Miner Res 1995; 10: 890-902.
43. Leslie WD, Tsang JF, Caetano PA, et al: Effectiveness of bone density measurement for predicting osteoporotic fractures in clinical practice. J Clin Endocrinol Metab 2007; 92: 77-81.